Nasdaq Halts Etoiles Capital Group Co., Ltd.

Novartis's U.S. shares dropped 4.5% after presenting MS pill trial data showing relapse rate reductions of 35.2% and 31.2% vs. Sanofi's Aubagio, below Roche's 51.1%-58.5% with fenebrutinib. No liver safety issues were observed. Analysts expected at least parity in efficacy. Novartis aims for long-term disease management.

Oric Pharmaceuticals reported that its drug enozertinib showed an 88% response rate in a study for EGFR lung cancer. The company plans to start a Phase 3 trial in 2027 and estimates a $2.5B U.S. market opportunity. Oric also continues studying enozertinib for other cancer types.

Piper Sandler maintained an Overweight rating and $145 price target on Sphere Entertainment, implying 30% upside from the Oct 22 close of $111.61. The firm cited long-term optimism and market recovery opportunities, despite current booking trends. Recent analyst price targets range from $125 to $180.

Piper Sandler kept a Neutral rating on RingCentral (RNG) with a $94 price target, an 18.4% upside from its Oct 22 close. The firm cited 6.4% ARR growth to $2.8B, exceeding expectations, but maintained caution due to market volatility and competition.

BP and Louisiana settled two disputes from the 2010 Deepwater Horizon oil spill. The agreement includes a $350M early payment and resolution of coastal zone lawsuits.

Blackstone's opportunistic real estate funds fell 3.2% in Q3 2026 due to writedowns on European properties and U.S. apartments, while core-plus funds rose 1.6%. Real estate AUM declined to $309B from $314.2B in Q2. Firmwide inflows remained strong at $63B for the quarter, but market conditions and geopolitical uncertainty impacted performance.